Firm announcement “N° 53 / 2024
Transactions in shares of Zealand Pharma (NASDAQ:) and/or associated securities by individuals exercising managerial obligations and/or their carefully related individuals
Copenhagen, Denmark, December 25, 2024 “Zealand Pharma A/S (Zealand) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology firm centered on the invention and improvement of progressive peptide-based medicines, has obtained details about transactions in Zealand Pharma’s shares or associated securities are held by individuals exercising managerial obligations and/or their carefully associated individuals and hereby publishes details about such transactions.
Please see the connected file(s).
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) is a biotechnology firm centered on the invention and improvement of peptide-based medicine. Greater than 10 Zeeland-invented drug candidates have reached scientific improvement, with two reaching the market and three candidates in late-stage improvement. The corporate has improvement and partnership agreements with quite a few pharmaceutical firms in addition to industrial partnerships for its marketed merchandise.
Zealand was based in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the USA. For extra data on Zealand’s enterprise and actions, please go to www.zealandpharma.com.
Contact:
Neshat Ahmadi (Traders)
Head of Investor Relations
E mail: neahmadi@zealandpharma.com
Adam Lange (Traders)
Investor Relations Officer
E mail: alange@zealandpharma.com
Anna Krassowska, PhD (Media and Traders)
Vice President, Investor Relations and Company Communications
E mail: akrassowska@zealandpharma.com
- 20241225 – Leonard Kruimer – Buy of shares
#Transactions #Zealand #Pharma #shares #andor #associated #securities #individuals #exercising #managerial #obligations #andor #carefully #associated #individuals , #Gossip247
,
